BioSpace News Archive

Antibe Therapeutics Inc. (TSXV: ATE, OTCQB: ATBPF), a clinical stage company leveraging its unique hydrogen sulfide platform to develop safer medicines for pain and inflammation, today announced that it has received final approval from the Toronto Stock Exchange (“TSX”) to list its common shares on the TSX. “We are excited to graduate to the TSX, as it represents a further step in reaching the broader investment community w

Genexine, Inc. and NeoImmuneTech, Inc. announced the release of data for the dose escalation phase of their Ph1b/2 study of GX-I7/NT-I7, a novel T cell amplifier, in combination with KEYTRUDA®, a leading checkpoint inhibitor, for the treatment of heavily pretreated patients with relapsed or refractory triple-negative breast cancer.

Former Celgene Executive and Immunotherapy Industry Leader to Drive Development Opportunities and Path-to-Market Initiatives for IMV’s Immunotherapy Pipeline

Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company focused on oncology and rare diseases, today announced that Dr. Denise Scots-Knight, Chief Executive Officer of Mereo will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20am Eastern Time. A live audio webcast of the presentation can be accessed through the Inve

Durable Complete Response Ongoingin HRD+ High Grade Serous Ovarian CancerPatient in Phase 1 Trial of PRT543

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV ® Technology Platform, today announced that two oral presentations will be presented at the American Academy Ophthalmology (AAO) 2020 Annual Meeting, ta

RLYB211 is in Clinical Development for the Prevention of FNAIT, a Potentially Life-Threatening Rare Disorder that Impacts Fetuses and Newborns

Lead antibody - ADG20 - expected to advance to clinical studies in early 2021, offers potential best-in-class treatment and durable protection against SARS-CoV-2 and future coronaviruses

Gemini Therapeutics, a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyenberg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the following investor conferences in November: Stifel 2020 Virtual Healthcare Conference Date: Tuesday, November 17

BELLUS Health Inc. announced that Roberto Bellini, BELLUS Health’s President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference.